ArticleCureus2024
Bilateral Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) Optic Neuritis: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optic neuritis (ON) is defined as an acquired disorder of the optic nerve that may be associated with demyelinating diseases or infectious or inflammatory processes. In children, the manifestation of this condition differs from that in adults, where it typically presents with bilateral papillitis subsequent to a preceding viral illness. Nonetheless, the main concern for practitioners is the possibility of its conversion to multiple sclerosis (MS). In recent years, there has been increased awareness regarding differentiating MS from other demyelinating ON phenotypes, namely, neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Despite the clinical similarities among these three entities, they vary in terms of pathophysiology, clinical course, treatment approaches, and prognostication. In this paper, we highlight the case of a child with MOGAD ON who was clinically severe at presentation and has typical features of ON and the appropriate investigation and treatment done to achieve complete visual recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.